CellWell record HH-104205
Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder
Lakshmi N. Yatham; Sidney H. Kennedy; Sagar V. Parikh; Ayal Schaffer; David J. Bond; Benício N. Frey; Verinder Sharma; Benjamin I. Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen
Bipolar Disorders · 2018
In plain language
These 2018 CANMAT and ISBD guidelines rank lithium, quetiapine, and other agents as first-line treatments for bipolar mania, depression, and maintenance therapy based on evidence for efficacy and safety.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-104205
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.